A Selective NF.KAPPA.B Inhibitor, DHMEQ, Reduced Atherosclerosis in ApoE-deficient mice
|
Accession number;07A0040470
|
| Title;A Selective NF.KAPPA.B Inhibitor, DHMEQ, Reduced Atherosclerosis in ApoE-deficient mice |
| Author;
CHIBA TSUYOSHI
(Geriatrics and Vascular Medicine, Tokyo Medical and Dental University Graduate School.)
KONDO YOSHITAKA
(Geriatrics and Vascular Medicine, Tokyo Medical and Dental University Graduate School.)
KONDO YOSHITAKA
(Tokyo Metropolitan Institute of Gerontology.)
SHINOZAKI SHOHEI
(Geriatrics and Vascular Medicine, Tokyo Medical and Dental University Graduate School.)
KANEKO EIJI
(Geriatrics and Vascular Medicine, Tokyo Medical and Dental University Graduate School.)
ISHIGAMI AKIHITO
(Tokyo Metropolitan Institute of Gerontology.)
MARUYAMA NAOKI
(Tokyo Metropolitan Institute of Gerontology.)
UMEZAWA KAZUO
(Department of Applied Chemistry Faculty of Science and Technology, Keio University.)
SHIMOKADO KENTARO
(Geriatrics and Vascular Medicine, Tokyo Medical and Dental University Graduate School.)
|
Journal Title;J Atheroscler Thromb
|
Journal Code:L2187A
|
ISSN:1340-3478
|
|
VOL.13;NO.6;PAGE.308-313 (J-STAGE)(2006)
|
| Figure&Table&Reference;FIG.3, TBL.1, REF.29 |
| Pub. Country;Japan |
| Language;English |
| Abstract;Background and Purpose: Atherosclerosis is a chronic inflammatory process, and anti-inflammatory agents potentially inhibit the development of atherosclerosis. We tested whether a novel NF.KAPPA.B inhibitor reduces atherosclerosis.Methods: Dehydroxymethylepoxyquinomicin (10 mg/kg) or vehicle (chloromethyl cellulose) was injected intraperitoneally into apoE-deficient mice three times a week for 16 weeks. The entire aorta was excised and atherosclerotic area was determined at 4 and 16 weeks. Serum levels of cholesterol, triglyceride, TNF-.ALPHA. and adiponectin were also measured.Results: The atherosclerotic area was significantly smaller in mice treated with dehydroxymethyl-epoxyquinomicin both at 4 and 16 weeks. There was no significant difference in body weight or serum levels of cholesterol, triglyceride, and adiponectin.Conclusions: A new NF.KAPPA.B inhibitor, dehydroxymethylepoxyquinomicin, reduced atherosclerosis without affecting plasma lipid levels in apoE-deficient mice. (Author abst.) |
|
|
|
Related Articles;
|
|
|
